Eduardo Cararo Lopes
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Eduardo Cararo Lopes has a total of 118 co-authors. Here are the top co-authors by number of shared publications:
- Eileen White
Rutgers Cancer Institute, Rutgers University, New Brunswick, USA
37 shared publications - Fuqian Shi
Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York University, New York, NY 10016, USA
34 shared publications - Joshua D. Rabinowitz
Department of Chemistry, Princeton University, Princeton, USA
33 shared publications - Akshada Sawant
Rutgers Cancer Institute, Rutgers University
31 shared publications - Chang S. Chan
Department of Medicine, Division of Medical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, USA
31 shared publications - Christian S. Hinrichs
Rutgers Cancer Institute, New Brunswick, NJ, USA
31 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2A from Immune Checkpoint Blockade Delays Cancer Development and Extends Survival in DNA Polymerase Mutator Syndromes
Supplementary Table 2A presents recurrently mutated genes in Pold1 D400A mutant tumor samples.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2A from Immune Checkpoint Blockade Delays Cancer Development and Extends Survival in DNA Polymerase Mutator Syndromes
Supplementary Table 2A presents recurrently mutated genes in Pold1 D400A mutant tumor samples.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from Immune Checkpoint Blockade Delays Cancer Development and Extends Survival in DNA Polymerase Mutator Syndromes
The figure presents the tumor incidence and mean survival plots for the Pold1 D400A and Pole L424V mice treated with immunotherapy before observable tumors appeared.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from Immune Checkpoint Blockade Delays Cancer Development and Extends Survival in DNA Polymerase Mutator Syndromes
The figure presents the tumor incidence and mean survival plots for the Pold1 D400A and Pole L424V mice treated with immunotherapy before observable tumors appeared.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1A from Immune Checkpoint Blockade Delays Cancer Development and Extends Survival in DNA Polymerase Mutator Syndromes
Supplementary Table 1A presents mutations exclusive to Pold1 D400A_10G mice compared to ancestral Pold1 D400A mice.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1A from Immune Checkpoint Blockade Delays Cancer Development and Extends Survival in DNA Polymerase Mutator Syndromes
Supplementary Table 1A presents mutations exclusive to Pold1 D400A_10G mice compared to ancestral Pold1 D400A mice.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1B from Immune Checkpoint Blockade Delays Cancer Development and Extends Survival in DNA Polymerase Mutator Syndromes
Supplementary Table 1B presents cancer associated genes in Pold1 D400A_10G tumor samples.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1B from Immune Checkpoint Blockade Delays Cancer Development and Extends Survival in DNA Polymerase Mutator Syndromes
Supplementary Table 1B presents cancer associated genes in Pold1 D400A_10G tumor samples.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3A from Immune Checkpoint Blockade Delays Cancer Development and Extends Survival in DNA Polymerase Mutator Syndromes
Supplementary Table 3A presents recurrently mutated genes in Pole mutant mouse models
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3A from Immune Checkpoint Blockade Delays Cancer Development and Extends Survival in DNA Polymerase Mutator Syndromes
Supplementary Table 3A presents recurrently mutated genes in Pole mutant mouse models
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 5 from Immune Checkpoint Blockade Delays Cancer Development and Extends Survival in DNA Polymerase Mutator Syndromes
Supplementary Table 5 presents recurrently mutated cancer genes in control antibody treated Pold1 D400A mutant mice.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 5 from Immune Checkpoint Blockade Delays Cancer Development and Extends Survival in DNA Polymerase Mutator Syndromes
Supplementary Table 5 presents recurrently mutated cancer genes in control antibody treated Pold1 D400A mutant mice.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Immune Checkpoint Blockade Delays Cancer Development and Extends Survival in DNA Polymerase Mutator Syndromes
The figure presents the representative images of Pold1 mutant tail tumors treated with immunotherapy.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Immune Checkpoint Blockade Delays Cancer Development and Extends Survival in DNA Polymerase Mutator Syndromes
The figure presents the representative images of Pold1 mutant tail tumors treated with immunotherapy.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from Immune Checkpoint Blockade Delays Cancer Development and Extends Survival in DNA Polymerase Mutator Syndromes
Supplementary Table 4 presents recurrently mutated cancer genes in anti-PD1 treated Pold1 D400A mutant mice.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from Immune Checkpoint Blockade Delays Cancer Development and Extends Survival in DNA Polymerase Mutator Syndromes
Supplementary Table 4 presents recurrently mutated cancer genes in anti-PD1 treated Pold1 D400A mutant mice.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2B from Immune Checkpoint Blockade Delays Cancer Development and Extends Survival in DNA Polymerase Mutator Syndromes
Supplementary Table 2B presents recurrently mutated genes from tumors of Pold1 D400A mice at allele frequency less than 0.5
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2B from Immune Checkpoint Blockade Delays Cancer Development and Extends Survival in DNA Polymerase Mutator Syndromes
Supplementary Table 2B presents recurrently mutated genes from tumors of Pold1 D400A mice at allele frequency less than 0.5
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3B from Immune Checkpoint Blockade Delays Cancer Development and Extends Survival in DNA Polymerase Mutator Syndromes
Supplementary Table 3B presents recurrently mutated genes in Pole mutant tumor samples at allele frequency less than 0.5
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3B from Immune Checkpoint Blockade Delays Cancer Development and Extends Survival in DNA Polymerase Mutator Syndromes
Supplementary Table 3B presents recurrently mutated genes in Pole mutant tumor samples at allele frequency less than 0.5